BridgeBio Oncology Therapeutics (BBOT) Leerink Global Healthcare Conference 2026 summary

Strategic focus and mission

• Accelerating scientific breakthroughs with a focus on high therapeutic index and tolerability for small molecule oncology drugs targeting RAS and PI3K alpha pathways.

• Three main clinical programs are advancing, all with readouts expected in the second half of 2026.

• Strong cash position of $425 million as of December 2025, expected to fund operations into 2028.

Clinical pipeline highlights

• BBO-8520, a direct on/off KRAS G12C inhibitor, showed 65% ORR in monotherapy and 68% six-month PFS, with differentiated tolerability and low liver toxicity in combination with pembrolizumab.

• BBO-11818, a pan-KRAS on/off inhibitor, demonstrated a partial response in pancreatic cancer and maintains a favorable safety profile during dose escalation.

• BBO-10203, a RAS PI3K breaker, blocks RAS-PI3K alpha interaction and showed no hyperglycemia or HbA1c restrictions in trials, with ongoing dose expansions.

Differentiation and combination strategies

• BBO-8520's on/off mechanism blocks effector binding in both protein states, potentially overcoming resistance seen with off-only inhibitors.

• Lower required drug levels for efficacy may reduce liver toxicity, enabling full-dose combinations with checkpoint inhibitors.

• Internal combinations of BBO-10203 with both BBO-11818 and BBO-8520 are planned, aiming for synergistic efficacy and improved safety.